Eledon Pharmaceuticals, Inc. - ELDN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Jul 31, 2026 | SCHEDULE 13G | Vanguard Capital Management | 5.05% | 3,898,446 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 6.8% | 5,382,084 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 6.8% | 5,382,084 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 2.7% | 2,057,090 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 2.7% | 2,057,090 | View |
| May 15, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.4% | 301,588 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.4% | 301,588 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.4% | 7,439,174 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.99% | 7,868,419 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.99% | 7,868,419 | View |
| May 15, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.99% | 7,868,419 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.